Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MajesTEC-9: teclistamab versus PVd or Kd in relapsed or refractory multiple myeloma
jRCT2041220125Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of teclistamab, pomalidomide, bortezomib, dexamethasone and carfilzomib in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-free survival and Number of participants reporting cytokine release syndrome cases by severity. Started May 2023; status: active, not recruiting.
02
Drugs
teclistamabpomalidomidebortezomibdexamethasonecarfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2041220125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220125.